Ultimovacs Investor Relations Material

Ultimovacs ASA is a pharmaceutical company. The company develops novel immunotherapies for the treatment and prevention of cancer. UV1, the company's lead product candidate, is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Their proprietary technology, including cancer vaccine platforms UV1 and TET, is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company aims to expands its pipeline using it novel TET-platform to generate multiple vaccine candidates designed to achieve increased T cell responses to a broad range of target antigens. Ultimovacs was incorporated in 2011 and is headquartered in Oslo, Norway, and has an additional office in Uppsala, Sweden.